ALGS NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Aligos Therapeutics Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 4.23 USD
3.7% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -35.0% below the Trend Line and sits at 2.6% of its 52-week range. The latest completed week returned 3.7%, after a -24.3% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 53/100. Near-term considerations: volume confirmation is below normal; earnings are due in 3d.

Setup score 20 out of 100
Latest Close 4.23 USD 31 Jul 2026
1W Return 3.7% latest completed week
4W Return -24.3% short-term follow-through
12W Return -34.3% quarterly tape
Trend Breadth 28.8% 15 of 52 weeks active
Volume Ratio 0.6x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 3.7% Latest completed week; four-week move -24.3%. Indicator stack 16/51 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 53/100 56 relevant articles in the latest sentiment read. Event risk 3d Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -35.0% below the Trend Line and sits at 2.6% of its 52-week range. The latest completed week returned 3.7%, after a -24.3% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.6x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0912-week average 0.03

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.09Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -24.3% over four weeks, -34.3% over 12 weeks, and -43.3% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W3.7%
4W-24.3%
12W-34.3%
26W-47.6%
52W-43.3%
Active trend streak0 weeks
Active weeks in one year15
Trend breadth28.8%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.24Latest activity-pressure read.
Pressure change63.4%Four-week change in activity pressure.
Leadership-51.12Latest relative-leadership reading.
RS change-26.2%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 76% Model confidence 73%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength74/100Blend of value, momentum, and quality. Underlying universe rank 27; rank 1 is best.
Value61/100Relative valuation strength. Underlying universe rank 40; rank 1 is best.
Quality60/100Profitability and accounting quality. Underlying universe rank 41; rank 1 is best.
Momentum62/100Medium-term price momentum. Underlying universe rank 39; rank 1 is best.
Growth62/100Revenue and earnings growth. Underlying universe rank 39; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
5.4x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-333.7%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
89.0%
Gross profit retained from each unit of revenue.
Operating margin
-1907.2%
Operating profit retained from revenue.
Free-cash-flow margin
-1790.8%
Free cash flow generated from revenue.
Return on invested capital
-1123.9%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
43.9%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
3/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-
Net share repurchases relative to market value.
Shareholder yield
-
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.3x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity6 / 0

6 acquisitions and 0 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment53/100

Weighted news tone is neutral across 56 relevant articles.

15 positive · 34 neutral · 7 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings3dNext report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-69.1%Distance below the 52-week high.
13-week volatility11.6%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2614 weeks finished lower.
Best week+19.7%Week of 3 Apr.
Worst week-28.9%Week of 24 Jul.
Latest week+3.7%Week of 31 Jul.

Shape of recent returns

Strong gains6
Modest gains5
Flat weeks1
Modest losses4
Sharp losses10
Recent vol11.6%13-week weekly-return volatility.
Base vol12.3%52-week weekly-return volatility.
Up/down split24/27Count of positive and negative weeks in the 52-week window.
Average skew8.9% / -8.6%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape24/100

Trend, activity pressure, participation, and risk combine to a 24/100 tape read.

 Indicator analysis10/100

Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.

Activity pressure 0.09; No reversal markers Factors64/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 50 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment53/100

Weighted news tone is neutral across 56 relevant articles.

Aligos Therapeutics to report results before markets open Aug. 6 Insiders6 / 0

6 acquisitions and 0 disposals in the latest 180-day insider tape.

 Earnings3d

Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20264.23 USD3.7%6.51 USD13.56 USD-0.24-51.12500.5KOff
24 Jul 20264.08 USD-28.9%6.67 USD13.68 USD-0.13-53.12554.5KOff
17 Jul 20265.74 USD-13.3%6.87 USD13.79 USD-0.04-36.09459.2KOff
10 Jul 20266.62 USD18.4%7.04 USD13.91 USD-0.23-30.204.7MOff
3 Jul 20265.59 USD0.4%7.26 USD14.03 USD-0.66-40.52298.3KOff
26 Jun 20265.57 USD5.5%7.41 USD14.15 USD-0.76-40.77314.6KOff
19 Jun 20265.28 USD0.0%7.54 USD14.27 USD-0.73-46.79324.7KOff
12 Jun 20265.28 USD7.5%7.67 USD14.39 USD-0.61-45.93305.8KOff
5 Jun 20264.91 USD-13.9%7.72 USD14.54 USD-0.52-49.09717.7KOff
29 May 20265.70 USD-1.0%7.79 USD14.68 USD-0.37-44.08476.1KOff
22 May 20265.76 USD0.9%7.87 USD14.84 USD-0.39-42.06633.9KOff
15 May 20265.71 USD-11.3%8.01 USD14.98 USD-0.37-42.09745.3KOff
8 May 20266.44 USD5.7%8.15 USD15.11 USD-0.25-35.19764.2KOff
1 May 20266.09 USD-4.8%8.25 USD15.24 USD-0.22-35.35571.3KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.